Lutetium-Psma
Oligometastasis
Medical University of ViennaradiopharmaceuticalActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
19 Active assets in the Oligometastasis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Degarelix VA Office of Research and Development | Phase 2/3 | B |
LEUPROLIDE VA Office of Research and Development | Phase 2/3 | B |
Apalutamide Medical University of Vienna | Phase 2/3 | B |
Flutamide VA Office of Research and Development | Phase 2/3 | B |
PREDNISONE TABLETS VA Office of Research and Development | Phase 2/3 | B |
View all 19 →
Same molecule, other indications
Lutetium-Psma is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →